Ozurdex (dexamethasone intravitreal implant) / AbbVie  >>  Phase 1
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ozurdex (dexamethasone intravitreal implant) / AbbVie
NCT02243124: A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Terminated
1
9
US
cenersen, Ol(1)p53, EL625, Aezea, Dexamethasone, Decadron, Maxidex, Ozurdex, Baycadron
Eleos, Inc., H. Lee Moffitt Cancer Center and Research Institute
Myelodysplastic Syndromes
09/15
12/15
NCT01204164: Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Completed
1
120
US
TG02 citrate, No other names., Carfilzomib, Kyprolis, Dexamethasone, Ozurdex, Maxidex, Decadron, Baycadron
Tragara Pharmaceuticals, Inc.
AML, ALL, Blast Crisis, MDS, Multiple Myeloma
03/16
04/16
NCT03000660: Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Terminated
1
3
US
Venetoclax, ABT-199, Dexamethasone, Ozurdex, Maxidex, Baycadron
Tufts Medical Center
AL Amyloidosis
10/19
10/19
NSABP FC-10, NCT03626922: Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Active, not recruiting
1
33
US
Pembrolizumab, Keytruda, Pemetrexed, Alimta, Oxaliplatin, Eloxatin, Dexamethasone, Ozurdex, Folic Acid, Vitamin B-12
NSABP Foundation Inc, Merck Sharp & Dohme LLC, Eli Lilly and Company
Metastatic Colorectal Cancer
10/21
11/22
NCT04082962: Dexamethasone Implant for Retinal Detachment in Uveal Melanoma

Completed
1
10
US
Dexamethasone intravitreal implant, Ozurdex™
Ivana K. Kim
Exudative Retinal Detachment and Uveal Melanoma
12/23
12/23
NCT03605719: Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Checkmark Updated results
Dec 2018 - Dec 2018: Updated results
Completed
1
23
US
Carfilzomib, Kyprolis, PR-171, Dexamethasone, Decadron, Hexadrol, Ozurdex, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pelareorep, Reolysin, Wild-type Reovirus
Emory University, Bristol-Myers Squibb, Oncolytics Biotech, University of Utah, City of Hope Medical Center, Phylogeny, National Cancer Institute (NCI), National Institutes of Health (NIH)
Recurrent Plasma Cell Myeloma
10/22
10/22
NCT04355039: INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Withdrawn
1
0
NA
Pomalidomide, Pomalyst, Dexamethasone, Ozurdex, INCB053914 50 mg bis in die (BID), pan-PIM Kinase Inhibitor, INCB053914 65 mg BID, INCB053914 80 mg BID
Medical College of Wisconsin
Refractory Multiple Myeloma, Relapse Multiple Myeloma
07/23
07/24
19-C-0042, NCT03805932: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruiting
1
18
US
Moxetumomab Pasudotox-tdfk, Lumoxiti, Rituximab, Rituxan, Ruxience, Rituximab-pvvr, Dexamethasone, Ozurdex, Maxidex, DexPak 6 Day, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Nytol, Banophen, Famotidine, Pepcid AC, Pepcid, Acid Controller, Aspirin, Ecotrin, Enteric Coated Aspirin, Buffered Aspirin
National Cancer Institute (NCI)
Hairy Cell Leukemia
07/23
06/25
NCT04840615: Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Terminated
1
2
US
LMB-100, ipilimumab, Yervoy, Diphenhydramine, Benadryl, Famotidine, Pepcid, Acetaminophen, Tylenol, Dexamethasone, Ozurdex, Biopsy, FDG-PET, Fluorodeoxyglucose-positron emission tomography, CT CAP, Computed tomography of the chest, abdomen and pelvis, MRI, Magnetic resonance imaging, ECG, Electrocardiogram, Echocardiogram, Echo
National Cancer Institute (NCI)
Mesothelioma
12/21
01/22
Anti-VEGF drugs combined with DEX for ME secondary to RVO, ChiCTR2400080048: Anti-VEGF drugs combined with dexamethasone implant for macular edeam secondary to retinal vein occlusion

Completed
1
60
 
The ranibizumab group, The patients received ranibizumab intravitreal injections in the first three months as the initial treatment. Patients might receive repeat injections during the follow-up in case of the recurrence of macular edema; The recurrence of macular edema is defined as the central macular thickness ≥ 300 um, or the increase of central macular thickness ≥ 50 um from the baseline.; The combination group (ranibizumab combined with dexamethasone intravitreal implant).In the combination group, patients received an intravitreal injection of dexamethasone implant after the first injection of ranibizumab at day 15. The recurrence of macular edema is defined as the central macular thickness ≥ 300 um, or the increase of central macular thickness ≥ 50 um from the baseline.
Sanmenxia Eye Hospital; Sanmenxia Eye Hospital, self-funding
macular edeam secondary to retinal vein occlusion
 
 

Download Options